Chronic myelogenous leukemia
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Chronic myelogenous leukemia Classification and external resources | |
 | |
|---|---|
| The Philadelphia chromosome as seen by metaphase FISH. | |
| ICD-10 | C92.1 |
| ICD-9 | 205.1 |
| ICD-O: | M9863/3 |
| DiseasesDB | 2659 |
| MedlinePlus | 000570 |
| eMedicine | med/371 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Chronic myelogenous leukemia (CML) is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. Historically, it has been treated with chemotherapy, interferon and bone marrow transplantation, although targeted therapies introduced at the beginning of the 21st century have radically changed the management of CML.
Epidemiology
CML occurs in all age groups, but most commonly in the middle-aged and elderly. Its annual incidence is 1–2 per 100,000 people, and slightly more men than women are affected. CML represents about 15–20% of all cases of adult leukemia in Western populations.[1] The only well-described risk factor for CML is exposure to ionizing radiation; for example, increased rates of CML were seen in people exposed to the atomic bombings of Hiroshima and Nagasaki.[1]
Signs and symptoms
Patients are often asymptomatic at diagnosis, presenting incidentally with an elevated white blood cell count on a routine laboratory test. In this setting, CML must be distinguished from a leukemoid reaction, which can have a similar appearance on a blood smear. Symptoms of CML may include: malaise, low-grade fever, gout, increased susceptibility to infections, anemia, and thrombocytopenia with easy bruising (although an increased platelet count (thrombocytosis) may also occur in CML). Splenomegaly may also be seen.[1][1]
Pathophysiology
CML was the first malignancy to be linked to a clear genetic abnormality, the chromosomal translocation known as the Philadelphia chromosome. This chromosomal abnormality is so named because it was first discovered and described in 1960 by two scientists from Philadelphia, Pennsylvania: Peter Nowell of the University of Pennsylvania and David Hungerford of the Fox Chase Cancer Center. [1]
In this translocation, parts of two chromosomes (the 9th and 22nd by conventional karyotypic numbering) switch places. As a result, part of the BCR ("breakpoint cluster region") gene from chromosome 22 is fused with the ABL gene on chromosome 9. This abnormal "fusion" gene generates a protein of p210 or sometimes p185 weight (p is a weight measure of cellular proteins in kDa). Because abl carries a domain that can add phosphate groups to tyrosine residues (a tyrosine kinase), the bcr-abl fusion gene product is also a tyrosine kinase.[1][1]
The fused bcr-abl protein interacts with the interleukin 3beta(c) receptor subunit. The bcr-abl transcript is continuously active and does not require activation by other cellular messaging proteins. In turn, bcr-abl activates a cascade of proteins which control the cell cycle, speeding up cell division. Moreover, the bcr-abl protein inhibits DNA repair, causing genomic instability and making the cell more susceptible to developing further genetic abnormalities. The action of the bcr-abl protein is the pathophysiologic cause of chronic myelogenous leukemia. With improved understanding of the nature of the bcr-abl protein and its action as a tyrosine kinase, targeted therapies have been developed (the first of which was imatinib mesylate) which specifically inhibit the activity of the bcr-abl protein. These tyrosine kinase inhibitors can induce complete remissions in CML, confirming the central importance of bcr-abl as the cause of CML.[1]
Diagnosis
CML is often suspected on the basis on the complete blood count, which shows increased granulocytes of all types, typically including immature myeloid cells. Basophils and eosinophils are almost universally increased; this feature may help differentiate CML from a leukemoid reaction. A bone marrow biopsy is often performed as part of the evaluation for CML, but bone marrow morphology alone is insufficient to diagnose CML.[1][1]
Ultimately, CML is diagnosed by detecting the Philadelphia chromosome. This characteristic chromosomal abnormality can be detected by routine cytogenetics, by fluorescent in situ hybridization, or by PCR for the bcr-abl fusion gene.[1]
Controversy exists over so-called Ph-negative CML, or cases of suspected CML in which the Philadelphia chromosome cannot be detected. Many such patients in fact have complex chromosomal abnormalities which mask the (9;22) translocation, or have evidence of the translocation by FISH or RT-PCR in spite of normal routine karyotyping.[1] The small subset of patients without detectable molecular evidence of bcr-abl fusion may be better classified as having an undifferentiated myelodysplastic/myeloproliferative disorder, as their clinical course tends to be different from patients with CML.[1]
Phases of CML
CML is often divided into three phases based on clinical characteristics and laboratory findings. In the absence of intervention, CML typically begins in the chronic phase, and over the course of several years progresses to an accelerated phase and ultimately to a blast crisis. Blast crisis is the terminal phase of CML and clinically behaves like an acute leukemia. One of the drivers of the progression from chronic phase through acceleration and blast crisis is the acquisition of new chromosomal abnormalities (in addition to the Philadelphia chromosome).[1] Some patients may already be in the accelerated phase or blast crisis by the time they are diagnosed.[1]
Chronic phase
Approximately 85% of patients with CML are in the chronic phase at the time of diagnosis. During this phase, patients are usually asymptomatic or have only mild symptoms of fatigue or abdominal fullness. The duration of chronic phase is variable and depends on how early the disease was diagnosed as well as the therapies used. Ultimately, in the absence of curative treatment, the disease progresses to an accelerated phase.[1]
Accelerated phase
Criteria for diagnosing transition into the accelerated phase are somewhat variable; the most widely used criteria are those put forward by investigators at M.D. Anderson Cancer Center,[1] by Sokal et al,[1] and the World Health Organization.[1][1] The WHO criteria are perhaps most widely used, and include:
- 10–19% myeloblasts in the blood or bone marrow
- >20% basophils in the blood or bone marrow
- Platelet count <100,000, unrelated to therapy
- Platelet count >1,000,000, unresponsive to therapy
- Cytogenetic evolution with new abnormalities in addition to the Philadelphia chromosome
- Increasing splenomegaly or white blood cell count, unresponsive to therapy
The patient is considered to be in the accelerated phase if any of the above are present. The accelerated phase is significant because it signals that the disease is progressing and transformation to blast crisis is imminent.[1]
Blast crisis
Blast crisis is the final phase in the evolution of CML, and behaves like an acute leukemia, with rapid progression and short survival.[1] Blast crisis is diagnosed if any of the following are present in a patient with CML:[1]
- >20% myeloblasts or lymphoblasts in the blood or bone marrow
- Large clusters of blasts in the bone marrow on biopsy
- Development of a chloroma (solid focus of leukemia outside the bone marrow)
Treatment
Chronic phase
Chronic phase CML is treated with inhibitors of tyrosine kinase , the first of which was imatinib mesylate (marketed as Gleevec® or Glivec®; previously known as STI-571). In the past, antimetabolites (e.g. cytarabine, hydroxyurea), alkylating agents, interferon alfa 2b, and steroids were used, but these drugs have been replaced by imatinib. Imatinib was approved by the United States FDA in 2001 and specifically targets BCR/abl, the constitutively activated tyrosine kinase fusion protein caused by the Philadelphia chromosome translocation. It is better tolerated and more effective than previous therapies. Bone marrow transplantation was also used as initial treatment for CML in younger patients before the advent of imatinib, and while it can often be curative, there is a high rate of transplant-related mortality.[1]
To overcome imatinib resistance and to increase responsiveness to TK inhibitors, two novel agents are currently undergoing clinical trials. The first, dasatinib, is a TK inhibitor that blocks several oncogenic proteins and has been recently approved by the US FDA to treat CML patients who are either resistant to or intolerant of imatinib. Dasatanib and Imatinib resistance is caused by the T315I mutation. One drug to overcome this resistance is being developed by Merck (MK-0457, formerly known as VX-680), however, enrollments in this clinical trial are currently suspended, pending a full analysis of all efficacy and safety data [1]. Another drug in development for the T315I mutation is Omacetaxine (formerly known as Ceflatonin®). Clinical data from the first 21 patients enrolled in a Phase 2/3 trial were presented at the American Society of Hematology (ASH) Annual Meeting [1]. Another agent, nilotinib, is a selective kinase inhibitor, but is currently undergoing clinical development and testing. Nilotinib is designed to bind more tightly than imatinib to the Bcr-Abl abnormal fusion protein responsible for chronic myeloid leukemia. Stem cell transplantation is a secondary option for treatment of CML.[1][1]
In 2005 favourable results of vaccination were reported with the BCR/abl p210 fusion protein in patients with stable disease, with GM-CSF as an adjuvant.[1]
Blast crisis
Blast crisis carries all the symptoms and characteristics of either acute myelogenous leukemia or acute lymphoblastic leukemia, and has a very high mortality rate. This stage can most effectively be treated by a bone marrow transplant after high-dose chemotherapy. In young patients in the accelerated phase, a transplant may also be an option. However the likelihood of relapse after a bone marrow transplant is higher in patients in blast crisis or in the accelerated phase as compared to patients in the chronic phase.[1]
Prognosis
In one analysis of several clinical studies, three different risk groups were identified based on a prognostic scoring system that includes several variables: age, spleen size, blast count, platelet count, eosinophil count and basophil count. In the lowest risk group, the median survival time was 98 months. In the middle group, the median was 65 months, and in the highest risk group, the median was about 42 months. Of all patients analyzed, the longest survival time was 117 months.[1] However, this study pre-dates the advent of treatments using targetted therapy. A follow-up on patients using imatinib published in the New England Journal of Medicine shows an overall survival rate of 89% after five years.[1]
References
External links
- The Leukemia & Lymphoma Society
- Blood & Marrow Transplant Information Network
- Association of Cancer Online Resource (ACOR) Leukemia Links
- Merck Manual:Chronic Myelocytic Leukemia (CML)
Pathology: hematology, myeloid hematologic disease (primarily D50-D77, 280-289) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RBCs/ hemoglobinopathy |
| ||||||||||||||||||||
| Coagulation/platelets/ coagulopathy/ bleeding diathesis |
| ||||||||||||||||||||
| Monocytes/ macrophages |
| ||||||||||||||||||||
| Granulocytes |
| ||||||||||||||||||||
| See also hematological malignancy and immune disorders | |||||||||||||||||||||
WikiDoc Research Resources for Chronic myelogenous leukemia | |
|---|---|
| Articles on Chronic myelogenous leukemia | Most recent articles on Chronic myelogenous leukemia • Most cited articles on Chronic myelogenous leukemia • Review articles on Chronic myelogenous leukemia • Articles on Chronic myelogenous leukemia in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Chronic myelogenous leukemia | Powerpoint slides on Chronic myelogenous leukemia • Images of Chronic myelogenous leukemia • Photos of Chronic myelogenous leukemia • Podcasts & MP3s on Chronic myelogenous leukemia • Videos on Chronic myelogenous leukemia |
| Evidence Based Medicine Regarding Chronic myelogenous leukemia | Cochrane Collaboration on Chronic myelogenous leukemia • Bandolier on Chronic myelogenous leukemia • TRIP on Chronic myelogenous leukemia |
| Cost Effectiveness of Chronic myelogenous leukemia | Cost Effectiveness of Chronic myelogenous leukemia |
| Clinical Trials Involving Chronic myelogenous leukemia | Ongoing Trials on Chronic myelogenous leukemia at Clinical Trials.gov • Trial results on Chronic myelogenous leukemia • Clinical Trials on Chronic myelogenous leukemia at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Chronic myelogenous leukemia | US National Guidelines Clearinghouse on Chronic myelogenous leukemia • NICE Guidance on Chronic myelogenous leukemia • NHS PRODIGY Guidance • FDA on Chronic myelogenous leukemia • CDC on Chronic myelogenous leukemia |
| Textbook Information on Chronic myelogenous leukemia | Books and Textbook Information on Chronic myelogenous leukemia |
| Pharmacology Resources on Chronic myelogenous leukemia | Dosing of Chronic myelogenous leukemia • Drug interactions with Chronic myelogenous leukemia • Side effects of Chronic myelogenous leukemia • Allergic reactions to Chronic myelogenous leukemia • Overdose information on Chronic myelogenous leukemia • Carcinogenicity information on Chronic myelogenous leukemia • Chronic myelogenous leukemia in pregnancy • Pharmacokinetics of Chronic myelogenous leukemia • |
| Genetics, Pharmacogenomics, and Proteinomics of Chronic myelogenous leukemia | Genetics of Chronic myelogenous leukemia • Pharmacogenomics of Chronic myelogenous leukemia • Proteomics of Chronic myelogenous leukemia |
| Newstories on Chronic myelogenous leukemia | Chronic myelogenous leukemia in the news • Be alerted to news on Chronic myelogenous leukemia • News trends on Chronic myelogenous leukemia |
| Commentary on Chronic myelogenous leukemia | Blogs on Chronic myelogenous leukemia |
| Patient Resources on Chronic myelogenous leukemia | Patient resources on Chronic myelogenous leukemia • Discussion groups on Chronic myelogenous leukemia • Patient Handouts on Chronic myelogenous leukemia • Directions to Hospitals Treating Chronic myelogenous leukemia • Risk calculators and risk factors for Chronic myelogenous leukemia |
| Healthcare Provider Resources on Chronic myelogenous leukemia | Symptoms of Chronic myelogenous leukemia • Causes & Risk Factors for Chronic myelogenous leukemia • Diagnostic studies for Chronic myelogenous leukemia • Treatment of Chronic myelogenous leukemia |
| Continuing Medical Education (CME) Programs on Chronic myelogenous leukemia | CME Programs on Chronic myelogenous leukemia |
| International Resources on Chronic myelogenous leukemia | Chronic myelogenous leukemia en Espanol • Chronic myelogenous leukemia en Francais |
| Business Resources on Chronic myelogenous leukemia | Chronic myelogenous leukemia in the Marketplace • Patents on Chronic myelogenous leukemia |
| Informatics Resources on Chronic myelogenous leukemia | List of terms related to Chronic myelogenous leukemia |
ar:ابيضاض الدم النقوي المزمن de:Chronische myeloische Leukämie fr:Leucémie myéloïde chronique ko:만성골수성백혈병 ms:Leukemia mielogenus kronik nl:Chronische myeloïde leukemie ja:慢性骨髄性白血病fi:Krooninen myelooinen leukemia sv:Kronisk myeloisk leukemi th:Chronic myelogenous leukemia
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
